Boehringer Ingelheim Signs €1.05 Billion Deal for Simcere's Preclinical IBD Bispecific SIM0709 on January 28, 2026 Antibodies, Bispecific Boehringer Ingelheim Inflammatory Bowel Diseases Interleukin-23 Subunit p19 SIM0709 Simcere TNFSF15 gene +
NextCure Partners with Simcere for Novel ADC in $745M Deal on June 17, 2025 ADC Antibody-Drug Conjugates CDH6 gene cellular targeting NextCure SIM0505 Simcere therapeutic autologous dendritic cells +